The increasing prevalence for muscle-building peptides has spawned a significant grey market, offering both intriguing possibilities and considerable risks. These shadowy products, often sourced from overseas manufacturers, bypass established pharmaceutical processes, allowing availability at lower prices. However, the lack of quality testing and s